BIOMAT Database Logo BIOMAT Database Logo

Prevention of gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study. 1994

J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Département d'Anesthésie, Hôpital de la Pitié-Salpétrière, Université Paris VI, France.

OBJECTIVE To evaluate the efficiency of intratracheal colistin in preventing nosocomial bronchopneumonia (BPN) in the critically ill. METHODS Study evaluating the clinical incidence of nosocomial BPN in 2 groups of critically ill patients who receive or did not receive intratracheal colistin. BPN was assessed clinically in survivors and histologically in non-survivors. METHODS A 14-bed surgical intensive care unit. METHODS 598 consecutive critically ill patients were studied during a prospective non-randomized study over a 40-month period. METHODS 251 patients--31 non-survivors and 220 survivors--did not receive intratracheal colistin and 347-42 non-survivors and 305 survivors--received intratracheal colistin for a 2-week period (1,600,000 units per 24 h). RESULTS The incidence of nosocomial BPN was evaluated clinically in survivors, using repeated protected minibronchoalveolar lavages, and histologically in non-survivors via an immediate postmortem pneumonectomy (histologic and semi-quantitative bacteriologic analysis of one lung). The clinical incidence of nosocomial BPN was of 37% in coli (-) survivors and of 27% in coli (+) survivors (p < 0.01). This result was histologically confirmed in non-survivors, where the incidence of histologic BPN was of 61% in coli (-) patients and of 36% in coli (+) patients (p < 0.001). Emergence of BPN due to colistin-resistant micro-organisms was not observed. Because colistin was successful in preventing Gram-negative BPN and did not change the absolute number of Gram-positive BPN, the proportion of BPN caused by staphylococcus species was higher in group coli (+) patients (33% vs 16%). Mortality was not significantly influenced by the administration of colistin. CONCLUSIONS This study suggests that the administration of intratracheal colistin during a 2-week period significantly reduces the incidence of Gram-negative BPN without creating an increasing number of BPN due to colistin-resistant micro-organisms.

UI MeSH Term Description Entries
D007322 Instillation, Drug The administration of therapeutic agents drop by drop, as eye drops, ear drops, or nose drops. It is also administered into a body space or cavity through a catheter. It differs from THERAPEUTIC IRRIGATION in that the irrigate is removed within minutes, but the instillate is left in place. Drug Instillation,Drug Instillations,Instillations, Drug
D007442 Intubation, Intratracheal A procedure involving placement of a tube into the trachea through the mouth or nose in order to provide a patient with oxygen and anesthesia. Intubation, Endotracheal,Endotracheal Intubation,Endotracheal Intubations,Intratracheal Intubation,Intratracheal Intubations,Intubations, Endotracheal,Intubations, Intratracheal
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011013 Pneumonectomy The excision of lung tissue including partial or total lung lobectomy. Bronchoscopic Lung Volume Reduction,Endoscopic Lung Volume Reduction,Lung Volume Reduction,Lung Volume Reduction Surgery,Partial Pneumonectomy,Partial Pneumonectomies,Pneumonectomies,Pneumonectomy, Partial,Reduction, Lung Volume,Volume Reduction, Lung
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D012121 Respiration, Artificial Any method of artificial breathing that employs mechanical or non-mechanical means to force the air into and out of the lungs. Artificial respiration or ventilation is used in individuals who have stopped breathing or have RESPIRATORY INSUFFICIENCY to increase their intake of oxygen (O2) and excretion of carbon dioxide (CO2). Ventilation, Mechanical,Mechanical Ventilation,Artificial Respiration,Artificial Respirations,Mechanical Ventilations,Respirations, Artificial,Ventilations, Mechanical
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids

Related Publications

J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects.
October 1992, The American review of respiratory disease,
J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients.
November 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study.
October 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients.
July 2013, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,
J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.
July 2013, European journal of clinical pharmacology,
J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Gram negative sinusitis: a bacteriologic and histologic study in rabbits.
January 1997, American journal of rhinology,
J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria.
January 2014, Antimicrobial agents and chemotherapy,
J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.
August 2009, Antimicrobial agents and chemotherapy,
J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients.
October 2003, Critical care (London, England),
J J Rouby, and P Poète, and E Martin de Lassale, and M H Nicolas, and L Bodin, and V Jarlier, and A M Korinek, and P Viars
Nosocomial gram-negative bacteremia in critically ill patients: epidemiologic characteristics and prognostic factors in 147 episodes.
July 1999, Journal of the Formosan Medical Association = Taiwan yi zhi,
Copied contents to your clipboard!